A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy (Neuron012703)
Recruitment status was Not yet recruiting
A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.
Chemotherapy Induced Neuropathy
Trauma Induced Neuropathy
Drug: Neuron012703 (Medical Food)
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy|
- VAS [ Time Frame: 60 Days ] [ Designated as safety issue: No ]To measure reduction in pain related to various types of peripheral neuropathy during administration of study intervention using a Visual Analog Scale.
- NTSS-6 [ Time Frame: 60 Days ] [ Designated as safety issue: No ]Neuropathy Total Symptom Score-6
- Routine Blood Panel [ Time Frame: 60 days ] [ Designated as safety issue: Yes ]CBC, Liver panel
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||July 2012|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
Drug: Neuron012703 (Medical Food)
2 capsules twice daily for sixty days.
Peripheral neuropathy is a disorder of the peripheral nerves—the motor, sensory and autonomic nerves that connect the spinal cord to muscles, skin and internal organs. It usually affects the hands and feet, causing weakness, numbness, tingling and pain. Peripheral neuropathy's course is variable; it can come and go, slowly progressing over many years, or it can become severe and debilitating. Peripheral neuropathy is common and it is estimated that upwards of 20 million Americans suffer from this illness. It can occur at any age, but is more common among elderly patients. In l999, a survey found that 8-9% of Medicare recipients have peripheral neuropathy as their primary or secondary diagnosis and the annual cost to Medicare exceeds $3.5 billion. Approximately 30% of peripheral neuropathy cases are linked to diabetes. Other common causes of neuropathy include autoimmune disorders, tumors, hereditary conditions, nutritional imbalances, infections or toxins. Another 30% of peripheral neuropathies are termed "idiopathic" when the cause is unknown. Pain in particular is a complex process initiated by pain-inducing or noxious stimuli interacting with pain receptors (nociceptors) which triggers a series of action potentials that are transmitted by neurotransmitters from peripheral afferent neurons to the spinal cord and higher nerve centers in the brain.
The study intervention is classified as a medical food that must be used under the active or ongoing supervision of a physician. Medical foods are developed to address the different or altered physiologic requirements that may exist for individuals with distinctive nutritional needs arising from metabolic disorders, chronic diseases, injuries, premature birth associated with inflammation and other medical conditions, as well as from pharmaceutical therapies. All of the ingredients included in the study intervention are classified as generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA). To qualify for GRAS status, a substance that is added to a food, including a medical food, has to be supported by data demonstrating that it is safe when consumed in amounts from these foods, as they are typically ingested or prescribed.
The study intervention is a proprietary blend of amino acids and antioxidants designed to target the cellular processes involved in the management of peripheral neuropathy symptoms. All of the ingredients are supplied in small milligram quantities which allows for safe and flexible dosing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01537705
|Contact: Francis Morfinemail@example.com|
|Contact: Stephanie Pavlik||3104749809 ext firstname.lastname@example.org|
|United States, California|
|Gabriel Halperin DPM Inc||Not yet recruiting|
|Los Angeles, California, United States, 90063|
|Contact: Francis Morfin 323-264-6187|
|Principal Investigator:||Gabriel Halperin, DPM||Gabriel Halperin DPM Inc.|